What is the main business of M-Peptides?

The main business activity of M-Peptides focuses on research and experimental development on biotechnology.

When was the company founded?

The company was registered in the Polish National Court Register (KRS) on September 22, 2017.

Where is the headquarters located?

The headquarters is located at: ul. Adolfa Pawińskiego 5A, 02-106 Warszawa.

Who is on the management board?

The management board consists of: Krzysztof Piotr Drabikowski (President of the Management Board) and Maciej Nikodem Paszewski (Member of the Management Board).

What is the share capital?

The share capital of the company is PLN 5,000 (approx. $1,351).

What period do the latest financial data cover?

The latest available financial statement covers the period from January 1, 2019 to December 31, 2019.

What revenue was generated?

In 2019, the company's revenue reached $2,448.

No, in 2019 the company reported a net loss of $895.

What is the largest operating cost?

The largest operating cost category falls under cost of goods and materials sold. This category amounted to $2,326 in 2019, representing 70% of all operating expenses.

M-Peptidessp. z o.o.

Research and experimental development on biotechnology

KRS: NIP: REGON:

Overview

Status

Suspended

Registry date

2017-09-22

Share capital

5,000.00 PLN

Registered address

ul. Adolfa Pawińskiego 5A, 02-106 Warszawa, Poland

Financials

Filing timeliness

No financial statement for 2020 – the filing deadline has passed.

2020not filed
201915/10/2020

Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Statistics

How the company ranks by revenue within its industry, region and across Poland in 2019.

Results vs industry

Revenue

This companyUSD 2.45kMedianUSD 55.24kAverageUSD 2.71m

Net profit

This companyUSD -894.51MedianUSD -1.27kAverageUSD -91.85k

Operating costs

This companyUSD 3.34kMedianUSD 65.85kAverageUSD 2.66m

Assets

This companyUSD 8.64kMedianUSD 133.19kAverageUSD 3.03m

Industry

Authorized Representatives

Krzysztof Piotr Drabikowski – President of the Management Board

Maciej Nikodem Paszewski – Management Board Member

Manner of representation

In the case of a one-person management board, the member of the management board makes declarations on behalf of the company. In the case of a management board consisting of two or more persons, joint action by two members of the management board or by one member of the management board jointly with a commercial proxy is required to make declarations on behalf of the company.

Ownership

Owner	Shares	Share value	Stake
Wojciech Balage 63	40	$540.25	40%
Krzysztof Piotr Drabikowskiage 56	40	$540.25	40%
Maciej Nikodem Paszewskiage 53	20	$270.12	20%

Beneficial owners

Person	Rights

Bank accounts

Was a VAT taxpayer from 2017-10-06 to 2025-02-25.

Reason for removal: Art. 96 ust. 6-8

Debt

No entries in the National Debtors Register (KRZ).

Public aid

Grant date	Purpose	Gross amount	Granting body
May 17, 2019	De minimis aid (in accordance with Commission Regulation No 1407/2013 or earlier)	$2,604$2,604	Uniwersytet Warszawski
Oct 6, 2017	Aid for SME access to finance — aid for start-ups	$53,248$53,248	IDEO sp. z o.o.

Competitors

Name	Revenue	Website
Frontline BiosciencesS.A.	$219,186.29	frontlinebiosciences.com
AI Corelabsp. z o.o.	$128,365.55	aicorelab.com
ModicaP.S.A.	$103,400.72	modica.bio
WPD Pharmaceuticalssp. z o.o.	$90,822.78	wpdpharmaceuticals.com
WPD PharmaceuticalsS.A.	$87,561.70	wpdpharmaceuticals.pl
Stenocoatsp. z o.o.	$36,665.21	stenocoat.com
Platforma Badań Genetycznychsp. z o.o.	$28,558.39	zdrowegeny.pl
Bioselsp. z o.o.	$19,100.32	selol.pl
Omnisepticasp. z o.o.	$3,475.29	omniseptica.com
Wavex Energysp. z o.o.	$142.33	wavexenergy.com